A binder that performs beautifully in phosphate-buffered saline (PBS) may fail completely in serum. Complex biological fluids contain thousands of proteins, lipids, and metabolites, any of which can interfere with binding through competitive, allosteric, or non-specific mechanisms.
NSB is the most common failure mode in serum. It manifests as:
- High reference channel signal in SPR/BLI: the analyte sticks to the sensor surface even without immobilized target.
- Super-stoichiometric binding in SEC: more analyte bound than the stoichiometry allows.
- Loss of activity over time: the binder is sequestered by serum components.
- Surface chemistry optimization: PEGylated sensor surfaces, carboxymethyl dextran, and polycarboxylate coatings reduce NSB.
- Buffer additives: 0.05% Tween-20, 1 mg/mL BSA, or 0.5 M NaCl can outcompete weak NSB interactions.
- Binder engineering: reducing surface hydrophobicity and optimizing charge distribution at the binder surface.
Even without NSB, serum components affect binding kinetics:
- Increased viscosity slows diffusion, reducing the apparent association rate (kₐ).
- Crowding agents can stabilize or destabilize the bound complex depending on the interface.
- Albumin and immunoglobulins, the most abundant serum proteins, rarely interfere directly but contribute to crowding effects.
- Viscosity correction: normalize kₐ by the relative viscosity of serum vs. buffer (∼1.3 for 50% human serum).
- Serum calibration curves: establish baseline kinetic parameters in buffer, then measure the same interaction in serum to quantify matrix effects.
- Depleted serum controls: use albumin/IgG-depleted serum to isolate specific interference sources.
A de novo EGFR binder designed by WeaveSeq showed:
| Condition | kₐ (M⁻¹s⁻¹) | k_d (s⁻¹) | K_D (nM) |
|---|
| PBS | 2.4 × 10⁵ | 3.1 × 10⁻⁴ | 1.3 |
| 50% serum | 1.1 × 10⁵ | 4.8 × 10⁻⁴ | 4.4 |
| 50% serum, PEG surface | 1.9 × 10⁵ | 3.4 × 10⁻⁴ | 1.8 |
The PEGylated sensor surface recovered most of the binding signal, confirming that NSB to the sensor, not serum protein interference with the binder itself, was the primary source of signal degradation.
- Always include a serum titration: measure binding at 0%, 10%, 25%, 50%, and 90% serum to quantify matrix effects.
- Report both buffer and serum kinetics: buffer kinetics demonstrate intrinsic affinity; serum kinetics demonstrate practical utility.
- Use orthogonal methods: confirm serum SPR/BLI results with SEC or ITC where possible.
WeaveSeq's validation protocols include standardized serum interference panels. Start a project to learn more.
Related reading: high-throughput validation of synthetic binders, scaffold engineering for multispecific binding, and geometric complementarity in interface engineering.
